<DOC>
	<DOCNO>NCT00484965</DOCNO>
	<brief_summary>The purpose study determine whether erythrocyte mediate dexamethasone delivery reduce circulate inflammatory marker coronary stent implantation improve clinical angiographic outcome .</brief_summary>
	<brief_title>Erythrocyte-Mediated Drug Delivery Prevention Stent Restenosis</brief_title>
	<detailed_description>In stent restenosis still unsolved problem . We know principally stent restenosis depend myointimal proliferation , biological process inflammatory mechanism play central role . We previously demonstrate immunosuppressive therapy prednisone administer 45 day stenting procedure reduce incidence restenosis six month clinical event 12 month high risk patient , persistent high C reactive protein level stenting implantation . But therapy need high dosage glucocorticoid , contraindication subset patient i.e . diabetic . Recently new method encapsulation drug human autologous erythrocyte use apparatus disposable kit develop . It 's well know blood erythrocyte change membrane property contact suspension different osmotic value . So developed method modify erythrocytes membrane property become porous able absorb release specific molecule . Experimental study demonstrate non diffusible pro-drug 21-phosphate dexamethasone load human blood erythrocyte slowly dephosphorylated correspond diffusible molecule release human plasma . Once in-vivo due presence hydrophilic phosphate group , Dex 21-P encapsulate RBCs diffuse RBC membrane slowly dephosphorylated correspond active corticosteroid erythrocytes resident enzyme . The novelty advantage procedure red blood cell act slow constant drug delivery system , 30 day administration , always low level corticosteroid plasma . When erythrocyte reinfused donor , release continuous way low constant level drug . This procedure yet use chronic inflammatory disease ( i.e . bowel disease ) 1600 patient , significant clinical improvement . The main objective study 1 ) evaluate autologous erythrocyte modify bioreceptor may use release glucocorticoid blood circulation 2 ) reduce acute inflammatory protein coronary stent implantation clinical angiographic outcome improvement . For purpose 100 patient undergoing coronary artery stent implantation prospectively randomize two group : 1. group A : bare metal stent implantation treatment 50 ml autologous erythrocyte charge dexamethasone 21-P 2. group B : bare metal stent implantation treatment 50 ml autologous erythrocyte charge dexamethasone 21-P The result two group compare .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Acute-Phase Reaction</mesh_term>
	<criteria>coronary disease write informed consent coronary stenosis CRP baseline level &lt; 0,5 mg/dl acute myocardial infarction coronary bypass graft restenosis vessel diameter &lt; 2,5 mm corticosteroid contraindication corticosteroid therapy 30 day active infective disease connective disease pregnancy cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Coronary stent</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Immunosuppressive</keyword>
</DOC>